Cargando…

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges

Mammalian target of rapamycin (mTOR) regulates cell proliferation, autophagy, and apoptosis by participating in multiple signaling pathways in the body. Studies have shown that the mTOR signaling pathway is also associated with cancer, arthritis, insulin resistance, osteoporosis, and other diseases....

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Zhilin, Tao, Tao, Li, Hongmei, Zhu, Xiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063815/
https://www.ncbi.nlm.nih.gov/pubmed/32175074
http://dx.doi.org/10.1186/s13578-020-00396-1
_version_ 1783504765681926144
author Zou, Zhilin
Tao, Tao
Li, Hongmei
Zhu, Xiao
author_facet Zou, Zhilin
Tao, Tao
Li, Hongmei
Zhu, Xiao
author_sort Zou, Zhilin
collection PubMed
description Mammalian target of rapamycin (mTOR) regulates cell proliferation, autophagy, and apoptosis by participating in multiple signaling pathways in the body. Studies have shown that the mTOR signaling pathway is also associated with cancer, arthritis, insulin resistance, osteoporosis, and other diseases. The mTOR signaling pathway, which is often activated in tumors, not only regulates gene transcription and protein synthesis to regulate cell proliferation and immune cell differentiation but also plays an important role in tumor metabolism. Therefore, the mTOR signaling pathway is a hot target in anti-tumor therapy research. In recent years, a variety of newly discovered mTOR inhibitors have entered clinical studies, and a variety of drugs have been proven to have high activity in combination with mTOR inhibitors. The purpose of this review is to introduce the role of mTOR signaling pathway on apoptosis, autophagy, growth, and metabolism of tumor cells, and to introduce the research progress of mTOR inhibitors in the tumor field.
format Online
Article
Text
id pubmed-7063815
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70638152020-03-13 mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges Zou, Zhilin Tao, Tao Li, Hongmei Zhu, Xiao Cell Biosci Review Mammalian target of rapamycin (mTOR) regulates cell proliferation, autophagy, and apoptosis by participating in multiple signaling pathways in the body. Studies have shown that the mTOR signaling pathway is also associated with cancer, arthritis, insulin resistance, osteoporosis, and other diseases. The mTOR signaling pathway, which is often activated in tumors, not only regulates gene transcription and protein synthesis to regulate cell proliferation and immune cell differentiation but also plays an important role in tumor metabolism. Therefore, the mTOR signaling pathway is a hot target in anti-tumor therapy research. In recent years, a variety of newly discovered mTOR inhibitors have entered clinical studies, and a variety of drugs have been proven to have high activity in combination with mTOR inhibitors. The purpose of this review is to introduce the role of mTOR signaling pathway on apoptosis, autophagy, growth, and metabolism of tumor cells, and to introduce the research progress of mTOR inhibitors in the tumor field. BioMed Central 2020-03-10 /pmc/articles/PMC7063815/ /pubmed/32175074 http://dx.doi.org/10.1186/s13578-020-00396-1 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Zou, Zhilin
Tao, Tao
Li, Hongmei
Zhu, Xiao
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
title mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
title_full mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
title_fullStr mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
title_full_unstemmed mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
title_short mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
title_sort mtor signaling pathway and mtor inhibitors in cancer: progress and challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063815/
https://www.ncbi.nlm.nih.gov/pubmed/32175074
http://dx.doi.org/10.1186/s13578-020-00396-1
work_keys_str_mv AT zouzhilin mtorsignalingpathwayandmtorinhibitorsincancerprogressandchallenges
AT taotao mtorsignalingpathwayandmtorinhibitorsincancerprogressandchallenges
AT lihongmei mtorsignalingpathwayandmtorinhibitorsincancerprogressandchallenges
AT zhuxiao mtorsignalingpathwayandmtorinhibitorsincancerprogressandchallenges